Hologic (HOLX) Completes Acquisition of Endomagnetics Ltd

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million.

“We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic. “With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention.”

The transaction adds Endomag’s wireless breast surgery localization and lymphatic tracing solutions – including the Magseed® marker, the Magtrace® lymphatic tracer and the Sentimag® platform – to Hologic’s breast surgery portfolio, providing breast surgeons and radiologists with an expanded range of options and enhanced user experience.

“We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians,” said Eric Mayes, PhD, Chief Executive Officer of Endomag. “As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”

You May Also Be Interested In

• Scinai posts H1 2026 results with wider operating loss, net gain
• Court awards TwinStrand $245.2M in Guardant Health patent case
• BKV registers 5.3 million shares for resale tied to power JV deal